Skip to main content
Erschienen in: Documenta Ophthalmologica 2/2020

25.02.2020 | Original Research Article

Macular function following intravitreal ranibizumab for macular edema associated with branch retinal vein occlusion: 12-month results

verfasst von: Tomoharu Nishimura, Shigeki Machida, Atsushi Tada, Eiki Oshida, Tetsuya Muto

Erschienen in: Documenta Ophthalmologica | Ausgabe 2/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To evaluate the 12-month effects of intravitral ranibizumab (IVR) injections on the physiology and morphology of the macula in eyes with a branch retinal vein occlusion with macular edema (BRVOME).

Methods

We studied 13 eyes of 13 patients with a BRVOME. All patients were initially treated with IVR injections at 3 consecutive monthly intervals, the initiation phase. Additional treatments were done according to the pro re nata (PRN) regimen. The physiology of the macula was assessed by the focal macular electroretinograms (fmERGs) and the best-corrected visual acuity (BCVA). The morphology of the macular area was determined by spectral-domain optical coherence tomography. The retina was assessed at the baseline, and at 3, 6, and 12 months after beginning the IVR injections. The fmERGs were elicited by a 15° circular stimulus, and also by 15° semicircular stimuli placed on the occluded or non-occluded side of the macula. The amplitudes of the a- and b-waves, photopic negative response (PhNR), and sums of the oscillatory potentials (ΣOPs) were measured. In addition, the implicit times of the a- and b-waves were measured.

Results

The BCVA was improved significantly relative to the baseline after the initiation phase (P < 0.01), and it was maintained with the PRN regimen for the 12-month experimental period. The foveal thickness was also significantly decreased after the initiation phase (P < 0.005) but was then worse at 12 months during the maintenance phase (P < 0.05). The fmERGs on the occluded side were significantly reduced at the baseline, and the b-waves and ΣOPs amplitudes improved after the initiation phase. However, they decreased during the PRN period. On the non-occluded side, the amplitudes and implicit times of the a- and b-waves remained unchanged after the initiation phase, the PhNR and ΣOPs amplitudes significantly increased at 3 months compared to the baseline (PhNR, P < 0.005; ΣOPs, P < 0.005), which was maintained throughout the 12 month study period.

Conclusions

The deterioration of the macular function on the occluded side during the maintenance phase suggests that there is a progression of the disease process during the PRN period in eyes with BRVOME.
Literatur
1.
Zurück zum Zitat Campochiaro PA, Heier JS, Feiner L, Gray S, Saroj N, Rundle AC, Murahashi WY, Rubio RG, Investigators BRAVO (2010) Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology 117:1102–1112CrossRef Campochiaro PA, Heier JS, Feiner L, Gray S, Saroj N, Rundle AC, Murahashi WY, Rubio RG, Investigators BRAVO (2010) Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology 117:1102–1112CrossRef
2.
Zurück zum Zitat Campochiaro PA, Clark WL, Boyer DS, Heier JS, Brown DM, Vitti R, Kazmi H, Berliner AJ, Erickson K, Chu KW, Soo Y, Cheng Y, Haller JA (2015) Intravitreal aflibercept for macular edema following branch retinal vein occlusion: the 24-week results of the VIBRANT study. Ophthalmology 122:538–544CrossRef Campochiaro PA, Clark WL, Boyer DS, Heier JS, Brown DM, Vitti R, Kazmi H, Berliner AJ, Erickson K, Chu KW, Soo Y, Cheng Y, Haller JA (2015) Intravitreal aflibercept for macular edema following branch retinal vein occlusion: the 24-week results of the VIBRANT study. Ophthalmology 122:538–544CrossRef
3.
Zurück zum Zitat Miyake Y, Yanagida K, Kondo K, Ota I (1981) Subjective scotometry and recording of local electroretinogram and visual evoked response. System with television monitor of the fundus. Jpn J Ophthalmol 25:439–448 Miyake Y, Yanagida K, Kondo K, Ota I (1981) Subjective scotometry and recording of local electroretinogram and visual evoked response. System with television monitor of the fundus. Jpn J Ophthalmol 25:439–448
4.
Zurück zum Zitat Miyake Y (1988) Studies on local macular ERG. Acta Soc Ophthalmol Jpn 92:1419–1449 Miyake Y (1988) Studies on local macular ERG. Acta Soc Ophthalmol Jpn 92:1419–1449
5.
Zurück zum Zitat Miyake Y (2006) Electrodiagnosis of retinal diseases. Springer, Tokyo Miyake Y (2006) Electrodiagnosis of retinal diseases. Springer, Tokyo
6.
Zurück zum Zitat Ogino K, Tsujikawa A, Murakami T, Muraoka Y, Akagi-Kurashige Y, Ishihara K, Miyamoto K, Nakamura H, Yoshimura N (2011) Evaluation of macular function using focal macular electroretinography in eyes with macular edema associated with branch retinal vein occlusion. Invest Ophthalmol Vis Sci 52:8047–8055CrossRef Ogino K, Tsujikawa A, Murakami T, Muraoka Y, Akagi-Kurashige Y, Ishihara K, Miyamoto K, Nakamura H, Yoshimura N (2011) Evaluation of macular function using focal macular electroretinography in eyes with macular edema associated with branch retinal vein occlusion. Invest Ophthalmol Vis Sci 52:8047–8055CrossRef
8.
Zurück zum Zitat Brown DM, Campochiaro PA, Bhisitkul RB, Ho AC, Gray S, Saroj N, Adamis AP, Rubio RG, Murahashi WY (2011) Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study. Ophthalmology 118:1594–1602CrossRef Brown DM, Campochiaro PA, Bhisitkul RB, Ho AC, Gray S, Saroj N, Adamis AP, Rubio RG, Murahashi WY (2011) Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study. Ophthalmology 118:1594–1602CrossRef
9.
Zurück zum Zitat Heier JS, Campochiaro PA, Yau L, Li Z, Saroj N, Rubio RG, Lai P (2012) Ranibizumab for macular edema due to retinal vein occlusions: long-term follow-up in the HORIZON trial. Ophthalmology 119:802–809CrossRef Heier JS, Campochiaro PA, Yau L, Li Z, Saroj N, Rubio RG, Lai P (2012) Ranibizumab for macular edema due to retinal vein occlusions: long-term follow-up in the HORIZON trial. Ophthalmology 119:802–809CrossRef
10.
Zurück zum Zitat Campochiaro PA, Sophie R, Pearlman J, Brown DM, Boyer DS, Heier JS, Marcus DM, Feiner L, Patel A, RETAIN Study Group (2014) Long-term outcomes in patients with retinal vein occlusion treated with ranibizumab: the RETAIN study. Ophthalmology 121:209–219CrossRef Campochiaro PA, Sophie R, Pearlman J, Brown DM, Boyer DS, Heier JS, Marcus DM, Feiner L, Patel A, RETAIN Study Group (2014) Long-term outcomes in patients with retinal vein occlusion treated with ranibizumab: the RETAIN study. Ophthalmology 121:209–219CrossRef
11.
Zurück zum Zitat Clark WL, Boyer DS, Heier JS, Brown DM, Haller JA, Vitti R, Kazmi H, Berliner AJ, Erickson K, Chu KW, Soo Y, Cheng Y, Campochiaro PA (2016) Intravitreal aflibercept for macular edema following branch retinal vein occlusion: 52-week results of the VIBRANT study. Ophthalmology 123:330–336CrossRef Clark WL, Boyer DS, Heier JS, Brown DM, Haller JA, Vitti R, Kazmi H, Berliner AJ, Erickson K, Chu KW, Soo Y, Cheng Y, Campochiaro PA (2016) Intravitreal aflibercept for macular edema following branch retinal vein occlusion: 52-week results of the VIBRANT study. Ophthalmology 123:330–336CrossRef
12.
Zurück zum Zitat Lalwani GA, Rosenfeld PJ, Fung AE, Dubovy SR, Michels S, Feuer W, Davis JL, Flynn HW Jr, Esquiabro M (2009) A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. Am J Ophthalmol 148:43–58CrossRef Lalwani GA, Rosenfeld PJ, Fung AE, Dubovy SR, Michels S, Feuer W, Davis JL, Flynn HW Jr, Esquiabro M (2009) A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. Am J Ophthalmol 148:43–58CrossRef
13.
Zurück zum Zitat Machida S, Toba Y, Ohtaki A, Gotoh Y, Kaneko M, Kurosaka D (2008) Photopic negative response of focal electroretinogram in glaucomatous eyes. Invest Ophthalmol Vis Sci 49:5636–5644CrossRef Machida S, Toba Y, Ohtaki A, Gotoh Y, Kaneko M, Kurosaka D (2008) Photopic negative response of focal electroretinogram in glaucomatous eyes. Invest Ophthalmol Vis Sci 49:5636–5644CrossRef
14.
Zurück zum Zitat The Central Vein Occlusion Study Group (1997) Natural history and clinical management of central retinal vein occlusion. Arch Ophthalmol 115:486–491CrossRef The Central Vein Occlusion Study Group (1997) Natural history and clinical management of central retinal vein occlusion. Arch Ophthalmol 115:486–491CrossRef
15.
Zurück zum Zitat Suzuki N, Hirano Y, Yoshida M, Tomiyasu T, Uemura A, Yasukawa T, Ogura Y (2016) Microvascular abnormalities on optical coherence tomography angiography in macular edema associated with branch retinal vein occlusion. Am J Ophthalmol 161:126–132CrossRef Suzuki N, Hirano Y, Yoshida M, Tomiyasu T, Uemura A, Yasukawa T, Ogura Y (2016) Microvascular abnormalities on optical coherence tomography angiography in macular edema associated with branch retinal vein occlusion. Am J Ophthalmol 161:126–132CrossRef
16.
Zurück zum Zitat Ogura Y, Kondo M, Kadonosono K, Shimura M, Kamei M, Tujikawa A (2019) Current practice in the management of branch retinal vein occlusion in Japan: survey results of retina specialists in Japan. Jpn J Ophthalmol 63:365–373CrossRef Ogura Y, Kondo M, Kadonosono K, Shimura M, Kamei M, Tujikawa A (2019) Current practice in the management of branch retinal vein occlusion in Japan: survey results of retina specialists in Japan. Jpn J Ophthalmol 63:365–373CrossRef
Metadaten
Titel
Macular function following intravitreal ranibizumab for macular edema associated with branch retinal vein occlusion: 12-month results
verfasst von
Tomoharu Nishimura
Shigeki Machida
Atsushi Tada
Eiki Oshida
Tetsuya Muto
Publikationsdatum
25.02.2020
Verlag
Springer Berlin Heidelberg
Erschienen in
Documenta Ophthalmologica / Ausgabe 2/2020
Print ISSN: 0012-4486
Elektronische ISSN: 1573-2622
DOI
https://doi.org/10.1007/s10633-020-09757-0

Weitere Artikel der Ausgabe 2/2020

Documenta Ophthalmologica 2/2020 Zur Ausgabe

Neu im Fachgebiet Augenheilkunde

Ophthalmika in der Schwangerschaft

Die Verwendung von Ophthalmika in der Schwangerschaft und Stillzeit stellt immer eine Off-label-Anwendung dar. Ein Einsatz von Arzneimitteln muss daher besonders sorgfältig auf sein Risiko-Nutzen-Verhältnis bewertet werden. In der vorliegenden …

Operative Therapie und Keimnachweis bei endogener Endophthalmitis

Vitrektomie Originalie

Die endogene Endophthalmitis ist eine hämatogen fortgeleitete, bakterielle oder fungale Infektion, die über choroidale oder retinale Gefäße in den Augapfel eingeschwemmt wird [ 1 – 3 ]. Von dort infiltrieren die Keime in die Netzhaut, den …

Bakterielle endogene Endophthalmitis

Vitrektomie Leitthema

Eine endogene Endophthalmitis stellt einen ophthalmologischen Notfall dar, der umgehender Diagnostik und Therapie bedarf. Es sollte mit geeigneten Methoden, wie beispielsweise dem Freiburger Endophthalmitis-Set, ein Keimnachweis erfolgen. Bei der …

So erreichen Sie eine bestmögliche Wundheilung der Kornea

Die bestmögliche Wundheilung der Kornea, insbesondere ohne die Ausbildung von lichtstreuenden Narben, ist oberstes Gebot, um einer dauerhaften Schädigung der Hornhaut frühzeitig entgegenzuwirken und die Funktion des Auges zu erhalten.   

Update Augenheilkunde

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.